ABL1 and breast carcinoma: Among the six identified drugs, bosutinib is a small molecule functioning as a dual inhibitor of BCR-ABL and Src tyrosine kinase for treating chronic myeloid leukemia (CML) and advanced solid tumors [72], including estrogen-positive breast cancer [73].